Jiangsu Lianhuan Pharmaceutical Co Ltd Total Assets
Jiangsu Lianhuan Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) holds total assets worth CN¥4.16 Billion CNY (≈ $608.23 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Jiangsu Lianhuan Pharmaceutical Co Ltd for the company's overall valuation and market capitalisation.
Total Assets of Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)
Total assets of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024. This chart illustrates how Jiangsu Lianhuan Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Jiangsu Lianhuan Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Jiangsu Lianhuan Pharmaceutical Co Ltd - Asset Composition Analysis
Jiangsu Lianhuan Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)
Jiangsu Lianhuan Pharmaceutical Co Ltd total assets breakdown as of December 2024. Jiangsu Lianhuan Pharmaceutical Co Ltd's total assets of CN¥4.16 Billion consist of 49.0% current assets and 51.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.5% |
| Accounts Receivable | CN¥631.04 Million | 20.9% |
| Inventory | CN¥439.32 Million | 14.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥258.77 Million | 8.6% |
| Goodwill | CN¥21.07 Million | 0.7% |
Asset Composition Trend (2000–2024)
This chart illustrates how Jiangsu Lianhuan Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Lianhuan Pharmaceutical Co Ltd's current assets represent 49.0% of total assets in 2024, a decrease from 65.3% in 2000.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, down from 13.4% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 10.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 20.9% of total assets.
Jiangsu Lianhuan Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Lianhuan Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Jiangsu Lianhuan Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.94 | 1.17 | 1.20 |
| Quick Ratio | 0.64 | 0.79 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-135.49 Million | CN¥256.89 Million | CN¥168.94 Million |
Jiangsu Lianhuan Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Lianhuan Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.81 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | CN¥3.02 Billion |
| Market Capitalization | $537.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Lianhuan Pharmaceutical Co Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jiangsu Lianhuan Pharmaceutical Co Ltd's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)
The table below shows the annual total assets of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.02 Billion ≈ $441.84 Million |
+5.73% |
| 2023-12-31 | CN¥2.86 Billion ≈ $417.88 Million |
+5.18% |
| 2022-12-31 | CN¥2.71 Billion ≈ $397.28 Million |
+15.29% |
| 2021-12-31 | CN¥2.35 Billion ≈ $344.58 Million |
+14.92% |
| 2020-12-31 | CN¥2.05 Billion ≈ $299.84 Million |
+8.44% |
| 2019-12-31 | CN¥1.89 Billion ≈ $276.51 Million |
+33.07% |
| 2018-12-31 | CN¥1.42 Billion ≈ $207.80 Million |
+21.95% |
| 2017-12-31 | CN¥1.16 Billion ≈ $170.40 Million |
+9.21% |
| 2016-12-31 | CN¥1.07 Billion ≈ $156.03 Million |
+6.57% |
| 2015-12-31 | CN¥1.00 Billion ≈ $146.41 Million |
+51.84% |
| 2014-12-31 | CN¥658.96 Million ≈ $96.43 Million |
+1.46% |
| 2013-12-31 | CN¥649.48 Million ≈ $95.04 Million |
+46.54% |
| 2012-12-31 | CN¥443.21 Million ≈ $64.86 Million |
+5.90% |
| 2011-12-31 | CN¥418.52 Million ≈ $61.24 Million |
+4.35% |
| 2010-12-31 | CN¥401.08 Million ≈ $58.69 Million |
+4.62% |
| 2009-12-31 | CN¥383.36 Million ≈ $56.10 Million |
+6.59% |
| 2008-12-31 | CN¥359.66 Million ≈ $52.63 Million |
+0.56% |
| 2007-12-31 | CN¥357.66 Million ≈ $52.34 Million |
+6.50% |
| 2006-12-31 | CN¥335.84 Million ≈ $49.14 Million |
+9.96% |
| 2005-12-31 | CN¥305.41 Million ≈ $44.69 Million |
-2.13% |
| 2004-12-31 | CN¥312.05 Million ≈ $45.66 Million |
+6.43% |
| 2003-12-31 | CN¥293.21 Million ≈ $42.91 Million |
+132.19% |
| 2002-12-31 | CN¥126.28 Million ≈ $18.48 Million |
+9.18% |
| 2001-12-31 | CN¥115.66 Million ≈ $16.93 Million |
+11.57% |
| 2000-12-31 | CN¥103.67 Million ≈ $15.17 Million |
-- |
About Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprili… Read more